1. Drew M,Pardoll 美国 Johns Hopkins University 2021美国医学院院士 Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
2. Topalian, Suzanne L. 美国 Johns Hopkins University 2017美国医学院院士 Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
3. Nathan E,Lewis 美国 University of California San Diego Computational cell-cell interaction technologies drive mechanistic and biomarker discovery in the tu..
4. 吴德沛 中国 苏州大学 主任医师 Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a ca..
5. Han,Liang 美国 University of Texas MD Anderson Cancer Center Single-cell dissection of tumor microenvironmental response and resistance to cancer therapy
6. Patrick M,Forde 美国 Johns Hopkins University Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
7. Barbara,Rothen-Rutishauser 瑞士 University of FRIBOURG Dual CSF1R inhibition and CD40 activation demonstrates anti-tumor activity in a 3D macrophage-HER2
8. Tonini, Giuseppe 意大利 University of Campus Biomed Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
9. Vincenzi, Bruno 意大利 University of Campus Biomed Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
10. Fortunato,Ciardiello 意大利 Second University of Naples Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..
11. Nathalie,Chaput 法国 UNIVERSITE PARIS SACLAY Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..
12. Benjamin,Besse 法国 Institute GUSTAVE ROUSSY Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..
13. Filippo,de Braud 意大利 Foundation IRCCS Ist Nazl Tumori Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..
14. Marina Chiara,Garassino 意大利 Foundation IRCCS Ist Nazl Tumori Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..
15. Valter,Torri 意大利 MARIO NEGRI Institute PHARMACOL Research Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combina..
16. Young Kwang,Chae 美国 Northwestern University risk factors for hyperprogressive disease in lung cancer patients using two different definitions
17. Yoon-Koo,Kang 韩国 University of Ulsan Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..
18. Martin,Reck 德国 Grosshansdorf Hospital Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..
19. Paul,Nghiem 美国 University of Washington Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..
20. Taofeek K,Owonikoko 美国 Emory University Assessment of hyperprogression versus the natural course of disease development with nivolumab with ..